Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory MyelofibrosisJohn Mascarenhas, Jean‐Jacques Kiladjian, Dietger Niederwieser et al.|Journal of Clinical Oncology|2021Cited by 107
Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose LevelsJohn Mascarenhas, Jean‐Jacques Kiladjian, Rami S. Komrokji et al.|Blood|2018Cited by 34